• Explore /
  • Poster
  • / A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody, in advanced cancers.

Abstract Poster

Authors

null

Kyriakos P. Papadopoulos

START, San Antonio, TX

Kyriakos P. Papadopoulos , Nehal J. Lakhani , Melissa Lynne Johnson , Haeseong Park , Ding Wang , Timothy Anthony Yap , Kathleen N. Moore , Tasha Nicholle Sims , Chetachi Emeremni , Maria Karasarides , Glenn Scott Kroog

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics and Translational Research

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03005782

Citation

J Clin Oncol 36, 2018 (suppl; abstr TPS3127)

DOI

10.1200/JCO.2018.36.15_suppl.TPS3127

Abstract #

TPS3127

Poster Bd #

328a

Abstract Disclosures

Similar Posters

Poster

2019 ASCO-SITC Clinical Immuno-Oncology Symposium

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.

A study of REGN3767, an anti-LAG-3 antibody, alone and in combination with cemiplimab (REGN2810), an anti-PD1 antibody in advanced cancers.

First Author: Kyriakos P. Papadopoulos

First Author: Omid Hamid

First Author: Nashat Gabrail

First Author: Judy S. Wang